



MarketVIEW: *Chlamydia trachomatis* vaccines

CAT No: VAMV003, published October 2008

REPORT ABSTRACT:

After the global success of new HPV vaccines focused on sexually transmitted infections, vaccine manufacturers are considering other high-burden infections in the adolescent group, especially *Chlamydia trachomatis* (CT). CT is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with *Chlamydia trachomatis* are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. Even after treatment re-infection rates of CT remain high with little chance of eradication within the population.

This **MarketVIEW** product is a comprehensive Excel-based model forecasting the potential commercial value of a prophylactic Chlamydia vaccine across the seven major markets. The model contains value (\$ m) and volume (mio doses) with predictions of launch timeframe, pricing and penetration. Using Gardasil adoption as a case study, the impact of country National Immunization Programs (NIPs) including “catch-up” campaigns are also included. The model tabulates all included assumptions and is easily adjusted with client modifications.

Model CONTENTS:

- Title page
- Value summary – seven major markets
- Volume summary – seven major markets
- Charts – volume
- Charts – value
- Females 10-12yrs
- US 10-12 yrs (primary segment)
- US 13-18 yrs (catch-up)
- UK 10-12 yrs (primary segment)
- UK 13-18 yrs (catch-up)
- Germany 10-12 yrs (primary segment)
- Germany 13-18 yrs (catch-up)
- France 10-12 yrs (primary segment)
- France 13-18 yrs (catch-up)
- Italy 10-12 yrs (primary segment)
- Italy 13-18 yrs (catch-up)
- Spain 10-12 yrs (primary segment)
- Spain 13-18 yrs (catch-up)
- Japan 10-12 yrs (primary segment)
- Japan 13-18 yrs (catch-up)
- Assumptions – major markets
- Assumptions – major markets (cont..)
- Competition IP landscape
- About VacZine Analytics

PAGES: Excel database

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines.

For more information please visit our website www.vacZine-analytics.com